Executives from Eyepoint Pharmaceuticals (NASDAQ:EYPT) told investors at RBC Capital Markets’ Ophthalmology Conference that ...

There are two types of macular degeneration: dry and wet. Dry age-related macular degeneration is the most common type — it ...

Apps may be available on your phone to help you monitor your wet AMD symptoms and assist you with everyday tasks such as reading, texting, and identifying objects. Advanced neovascular age-related ...

What it is. AXPAXLI (OTX-TKI) is an investigational, bioresorbable intravitreal hydrogel implant designed to continuously ...

A dual VEGF-A and angiopoietin-2 inhibitor provided fast, durable treatment for wet age-related macular degeneration in a ...

—A new analysis took a 2-prong approach to assessing risk factors for wet age-related macular degeneration: a systematic review of the literature, coupled with a study of decades’ worth of data from ...

EyePoint Pharmaceuticals’ investigational therapy for wet age-related macular degeneration (wet AMD) was effective in a Phase 2 trial, the company announced Monday. The announcement was welcome news ...

311 subjects have been enrolled in the SOL-R study for AXPAXLI, demonstrating strong recruitment progress and enthusiasm within the retina community. The SOL-1 trial has completed randomization ahead ...

This is a quickly progressing field, according to Sarju Patel, MD, attending physician at Retinal Consultants of America. He has high expectations that advances from subtly tinted eyeglass lenses to ...

Every day tech, like your smartphone or computer, can help manage wet AMD through built-in accessibility features such as voice commands, screen magnification, and high-contrast settings.